Abbott Laboratories (ABT *) Stock Overview
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
ABT * Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Abbott Laboratories Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2,364.60 |
| 52 Week High | US$2,915.60 |
| 52 Week Low | US$2,235.50 |
| Beta | 0.72 |
| 1 Month Change | 1.16% |
| 3 Month Change | -2.77% |
| 1 Year Change | 0.19% |
| 3 Year Change | 14.51% |
| 5 Year Change | 9.34% |
| Change since IPO | 302.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| ABT * | MX Medical Equipment | MX Market | |
|---|---|---|---|
| 7D | -0.2% | 0% | 0% |
| 1Y | 0.2% | 0% | 0% |
Return vs Industry: ABT * underperformed the MX Medical Equipment industry which returned 1.5% over the past year.
Return vs Market: ABT * underperformed the MX Market which returned 20.5% over the past year.
Price Volatility
| ABT * volatility | |
|---|---|
| ABT * Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: ABT *'s share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine ABT *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1888 | 114,000 | Robert Ford | www.abbott.com |
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Abbott Laboratories Fundamentals Summary
| ABT * fundamental statistics | |
|---|---|
| Market cap | Mex$4.10t |
| Earnings (TTM) | Mex$254.87b |
| Revenue (TTM) | Mex$802.41b |
Is ABT * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABT * income statement (TTM) | |
|---|---|
| Revenue | US$43.84b |
| Cost of Revenue | US$19.18b |
| Gross Profit | US$24.67b |
| Other Expenses | US$10.74b |
| Earnings | US$13.93b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 8.01 |
| Gross Margin | 56.26% |
| Net Profit Margin | 31.76% |
| Debt/Equity Ratio | 25.3% |
How did ABT * perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/29 19:58 |
| End of Day Share Price | 2025/11/24 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Abbott Laboratories is covered by 55 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Adam Feinstein | Barclays |
| Matthew Miksic | Barclays |